Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

An antibody-drug conjugate directed to the ALK receptor demonstrates efficacy in preclinical models of neuroblastoma.

Sano R, Krytska K, Larmour CE, Raman P, Martinez D, Ligon GF, Lillquist JS, Cucchi U, Orsini P, Rizzi S, Pawel BR, Alvarado D, Mossé YP.

Sci Transl Med. 2019 Mar 13;11(483). pii: eaau9732. doi: 10.1126/scitranslmed.aau9732.

PMID:
30867324
2.

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.

Alvarado D, Ligon GF, Lillquist JS, Seibel SB, Wallweber G, Neumeister VM, Rimm DL, McMahon G, LaVallee TM.

PLoS One. 2017 Jul 19;12(7):e0181356. doi: 10.1371/journal.pone.0181356. eCollection 2017.

3.

Inhibition of ErbB3 by a monoclonal antibody that locks the extracellular domain in an inactive configuration.

Lee S, Greenlee EB, Amick JR, Ligon GF, Lillquist JS, Natoli EJ Jr, Hadari Y, Alvarado D, Schlessinger J.

Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):13225-30. doi: 10.1073/pnas.1518361112. Epub 2015 Oct 12.

4.

Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK.

Murray PB, Lax I, Reshetnyak A, Ligon GF, Lillquist JS, Natoli EJ Jr, Shi X, Folta-Stogniew E, Gunel M, Alvarado D, Schlessinger J.

Sci Signal. 2015 Jan 20;8(360):ra6. doi: 10.1126/scisignal.2005916.

PMID:
25605972
5.

Flavonoids inhibit cytokine-induced endothelial cell adhesion protein gene expression.

Gerritsen ME, Carley WW, Ranges GE, Shen CP, Phan SA, Ligon GF, Perry CA.

Am J Pathol. 1995 Aug;147(2):278-92.

Supplemental Content

Loading ...
Support Center